Prospective validation of a pharmacogenetic test: The PREDICT-1 study;Validación prospectiva de un test farmacogenético: Estudio PREDICT-1

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 6, 2008, Pages 40-44

  Muñoz De Benito, Rosa M ^a   Arribas López, José Ramón ^b  

^a Hospital del Norte   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Abacavir; Epicutaneous test; HLA B*5701; Hypersensitivity reaction; Pharmacogenetics

Indexed keywords

ABACAVIR; HLA B57 ANTIGEN; HLA B5701; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PATCH TEST; PATIENT MONITORING; PHARMACOGENETICS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MASS SCREENING; PHARMACOGENETICS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 75449116194     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76511-X     Document Type: Article

References (21)

1. K.A. Philips, D.L. Veenstra, and E. Oren Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 2001 2270 2279 (Pubitemid 33063150)
2. S. Hethrerington, S. McGuirk, and G. Powell Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir Clin Ther 23 2001 1603 1614 (Pubitemid 33063588)
3. L. Escaut, J.Y. Liotoer, and E. Albengres Abacavir rechallenge has to be avoided in case of hypersensitivity reaction AIDS 13 1999 1419 1420 (Pubitemid 29408463)
4. A.G. Cutrell, J.E. Hernández, and J.W. Fleming et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir Ann Pharmacother 38 2004 2171 2172
5. C. Brothers, P. Wannamaker, and D. Sutherland-Philips Lower reported rate of suspected hypersensitivity reaction to Abacavir among black patients 46th ICAAC San Francisco 2006 Abstract H-1065
6. P.J. Easterbrook, A. Waters, and S. Murad Epidemiological risk factors for hypersensitivity reactions to abacavir HIV Med 4 2003 321 324 (Pubitemid 37304372)
7. S. Mallal, D. Nolan, and C. Witt Association between presence of HLA-B* 5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir Lancet 459 2002 727 732 (Pubitemid 34215071)
8. S. Hethrerington, A.R. Hughes, and M. Mosteller Genetic variations in HLA-B regionand hypersensitivity reactions to abacavir Lancet 359 2002 1121 1122 (Pubitemid 34270738)
9. A.M. Martin, D. Nolan, and S. Gaudieri Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotipic Hsp70-Hom variant Proc Natl Acad Sci U S A 101 2004 4180 4185 (Pubitemid 38405903)
10. M. Mosteller, A. Hughes, and L. Warren et al. Pharmacogenetic investigations of hypersensitivity to Abacavir 16th International AIDS Conferece. Toronto 2006 Abstract WEPE0171
11. D.A. Hughes, F.J. Vilar, and C.C. Ward et al. Cost-effectiveness análisis of HLA-B5701 genotyping in preventing abacavir hypersensitivity Pharmacogenetics 14 2004 335 342
12. K. Cao, J. Hollenbach, and X. Shi et al. Analysis of the frequency of HLA-A, B an C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations Human Immunology 62 2001 1009 1020
13. Saag M, Balu R, Brachman P. High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of Abacavir hypersensitivity. 4th IAS Conference on HIV pathogenesis, treatment and prevention. Sydney 2.007. Abstract WEAB305.
14. McCluskey J, Chessman D, Lethborg T, et al. Abacavir hypersensitivity HLA-B*5701 positive idividuals with HIV infection is dependent upon the conventional MHC-I Ag presentation pathway. 4th IAS Conference on HIV pathogenesis, treatment and prevention. Sydney 2.007. Abstract WEAB3LB.
15. A. Rauch, D. Nolan, and A. Martin Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western-australian HIV cohort study Clin Infect Dis 43 2006 99 102 (Pubitemid 43939082)
16. I. Reeves, D. Churchill, and M. Fisher Clinical utility of HLA-B*5701 testing in a UK clinic cohort 12th Anual Conference of the British HIV Association. Brighton 2006 Oral Abstract O19
17. l. Waters, S. Mandalia, and Gazzard et al. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience AIDS 21 2000 2533 2597
18. Philips E, Rauch A, Nolan D, et al. Pharmacogenetics and clinical characteristics of patch test confirmed patients with Abacavir hypersensitivity. Rev Antivir Ther. 2066;3:57.
19. E.J. Philips, J.R. Sullivan, and S.R. Knowles Utility of patch testing in patients with hypersensitivity syndromes associated with Abacavir AIDS 16 2002 2223 2225
20. S. Mallal, E. Philips, and G. Carosi et al. PREDICT-1: a novel randomized prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-infected subjects (study CNA 106030) 4th IAS Conference on HIV pathogenesis, treatment and prevention. Sydney 2007 Abstract WESS 101
21. Guidelines for the use of Antiretroviral agents in HIV-1 infected adults and adolescents. Dec 1, 2007. DHHS Panel. Disponible en: http://AIDSinfo.nih. gov.